These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9704708)

  • 1. Clinical significance of alpha-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer.
    Anttila M; Kosma VM; Ji H; Wei-Ling X; Puolakka J; Juhola M; Saarikoski S; Syrjänen K
    J Clin Oncol; 1998 Aug; 16(8):2591-600. PubMed ID: 9704708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of p53 immunostaining in epithelial ovarian cancer.
    Hartmann LC; Podratz KC; Keeney GL; Kamel NA; Edmonson JH; Grill JP; Su JQ; Katzmann JA; Roche PC
    J Clin Oncol; 1994 Jan; 12(1):64-9. PubMed ID: 8270986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas.
    Salvesen HB; Iversen OE; Akslen LA
    Clin Cancer Res; 1998 Nov; 4(11):2779-85. PubMed ID: 9829742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer.
    Voutilainen KA; Anttila MA; Sillanpää SM; Ropponen KM; Saarikoski SV; Juhola MT; Kosma VM
    J Clin Pathol; 2006 May; 59(5):460-7. PubMed ID: 16461565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.
    Bačić B; Haller H; Mrklić I; Košta V; Čarić A; Tomić S
    Arch Gynecol Obstet; 2013 Jun; 287(6):1219-24. PubMed ID: 23269354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
    Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
    Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of beta-catenin is associated with poor survival in ovarian carcinomas.
    Faleiro-Rodrigues C; Macedo-Pinto I; Pereira D; Lopes CS
    Int J Gynecol Pathol; 2004 Oct; 23(4):337-46. PubMed ID: 15381903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study.
    Salvesen HB; Iversen OE; Akslen LA
    J Clin Oncol; 1999 May; 17(5):1382-90. PubMed ID: 10334522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
    Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
    Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical patterns for alpha- and beta-catenin, E- and N-cadherin expression in ovarian epithelial tumors.
    Marques FR; Fonsechi-Carvasan GA; De Angelo Andrade LA; Böttcher-Luiz F
    Gynecol Oncol; 2004 Jul; 94(1):16-24. PubMed ID: 15262114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear β-catenin positivity as a predictive marker of long-term survival in advanced epithelial ovarian cancer.
    Nagy B; Tóth L; Molnár P; Méhes G; Thurzó L; Póka R; Hernádi Z
    Pathol Res Pract; 2017 Aug; 213(8):915-921. PubMed ID: 28651933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas.
    Aune G; Stunes AK; Tingulstad S; Salvesen O; Syversen U; Torp SH
    Int J Clin Exp Pathol; 2011 Jun; 4(5):444-53. PubMed ID: 21738816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
    Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP
    Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal immunoreactivity of the E-cadherin/catenin (alpha-, beta-, and gamma-) complex in premalignant and malignant non-melanocytic skin tumours.
    Papadavid E; Pignatelli M; Zakynthinos S; Krausz T; Chu AC
    J Pathol; 2002 Feb; 196(2):154-62. PubMed ID: 11793366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative studies on the biological significance of the marker for proliferation Ki-67-Antigen and PCNA in primary ovarian carcinoma].
    Reitmaier M; Rudlowski C; Biesterfeld S; Rath W; Schröder W
    Zentralbl Gynakol; 2000; 122(7):361-7. PubMed ID: 10951706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma.
    Klemi PJ; Pylkkänen L; Kiilholma P; Kurvinen K; Joensuu H
    Cancer; 1995 Oct; 76(7):1201-8. PubMed ID: 8630898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma.
    Levesque MA; Katsaros D; Yu H; Zola P; Sismondi P; Giardina G; Diamandis EP
    Cancer; 1995 Mar; 75(6):1327-38. PubMed ID: 7882283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ErbB-3 predicts survival in ovarian cancer.
    Tanner B; Hasenclever D; Stern K; Schormann W; Bezler M; Hermes M; Brulport M; Bauer A; Schiffer IB; Gebhard S; Schmidt M; Steiner E; Sehouli J; Edelmann J; Läuter J; Lessig R; Krishnamurthi K; Ullrich A; Hengstler JG
    J Clin Oncol; 2006 Sep; 24(26):4317-23. PubMed ID: 16896008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer.
    Anttila MA; Kosma VM; Hongxiu J; Puolakka J; Juhola M; Saarikoski S; Syrjänen K
    Br J Cancer; 1999 Apr; 79(11-12):1870-8. PubMed ID: 10206307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic markers in ovarian carcinoma--retrospective study].
    Tomsová M; Melichar B; Sedláková I; Nová M
    Cesk Patol; 2005 Apr; 41(2):51-9. PubMed ID: 15966333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.